MCCULLOUGH ROBERTSON advised Tissue Therapies Limited on its rights issue prospectus to raise around $3.37 million, which was sent to shareholders last week.
Tissue Therapies will use the funds raised to further develop its VitroGro technology into a more effective treatment for wounds and burns, as well as integrating it with orthopaedic and medical implants.
“The work done to facilitate this capital raising was made all the more important as the additional funds will make a very real impact on those who need this product and its advancements — burn and wound victims from around the world,” said Reece Walker, one of the lead lawyers on the deal.
“Recent events have firmly highlighted the need for these sorts of treatments. The team and firm were delighted to assist Tissue Therapies in putting this prospectus together.”
Director of Tissue Therapies, Greg Baynton, said the “legal know how” and “professionalism” of McCullough Robertson’s team in getting the prospectus completed and to shareholders was “commendable”.